Scholars Central

Conference abstractPublished 27 Oct 2014

Challenges for biosimilar generics

Authors: Vivek Kashyap

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars are recombinantly produced drugs and are similar to reference biologic. Although, defined, specific and well planned guidelines for Biosimilars are available world-wide, yet the biosimilar drugs face lot of challenge from the patenting strategies from their innovator competitors. Interestingly, most of the innovators not only protect their Biopharmaceuticals in form of product patents but also in form of formulations, delivery systems, preparing methods and their use. However, the biosimilar generics face even a greater challenge from innovator?s devising strategies for developing better and enhanced efficacious Biopharmaceuticals than the existing ones, as the new and improved versions of Biopharmaceuticals can be of concern for biosimilar generics. Therefore it is pertinent for biosimilar generics to understand the patenting strategies of the innovators for Biopharmaceuticals they have developed. In addition, the biosimilar generics need also undertake a comprehensive review of the prosecution strategies of the innovators, which can provide them a good insight to prevent any legal issues.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Vivek Kashyap”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels